TriSalus' $22 Million Private Placement and Strategic Initiatives

TriSalus Life Sciences has announced a $22 million private placement to support its ongoing efforts in improving treatment outcomes for patients with solid tumors, particularly in the liver and pancreas. The funds are raised through a securities purchase agreement with investors including Nantahala Capital and Broadfin Holdings, with Canaccord Genuity serving as the placement agent. In conjunction with the financing, TriSalus plans to streamline its capital structure by launching an exchange offer for its Series A Convertible Preferred Stock to convert it into common stock. Additionally, preliminary unaudited financial results for Q1 2025 indicate a 42% revenue increase from the previous year, fueled by their TriNav Infusion System. The company is emphasizing its Pressure-Enabled Drug Delivery (PEDD) technology designed to enhance therapeutic delivery and effectiveness while limiting collateral damage to healthy tissue. TriSalus intends to register the newly issued common stock with the SEC and plans to use the proceeds for working capital and general corporate purposes. They are also seeking to file amendments with the SEC that could simplify their capital structure and align stakeholders through a special meeting by Q3 2025.